References
- Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999; 163: 1521–8
- Lin J, Ziring D, Desai S, Kim S, Wong M, Korin Y, et al. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008; 126: 13–30
- Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005; 52: 2513–18
- Voulgari PV, Markatseli TE, Exarchou SA, Zioga A, Drosos AA. Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis 2008; 67: 567–70
- Devos SA, Van Den Bossche N, De Vos M, Naeyaert JM. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology 2003; 206: 388–90
- Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005; 7: R666–76
- Perez-Zafrilla B, Garcia de Yebenes M, Dauden E, Gomez-Reino JJ, Carmona L. Is psoriasis a complication of anti-TNF treatment?. Arthritis Rheum 2008; 58(Suppl)S781
- Nestle FO, Gilliet M. Defining upstream elements of psoriasis pathogenesis: an emerging role for interferon alpha. J Invest Dermatol 2005; 125: xiv–xv
- Alexander JS, Paniker PU. A ring-shaped eruption. Am J Med 2006; 119: 125–7
- Sfikakis PP, Kollias G. Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol 2003; 15: 380–6
- Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 2003; 30: 2287–91
- De Miguel S, Jover JA, Vadillo C, Judez E, Loza E, Fernandez-Gutierrez B. B cell activation in rheumatoid arthritis patients under infliximab treatment. Clin Exp Rheumatol 2003; 21: 726–32
- Lamprecht P, Voswinkel J, Lilienthal T, Nolle B, Heller M, Gross WL, et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002; 41: 1303–7
- Arbach O, Gross WL, Gause A. Treatment of refractory Churg–Strauss-Syndrome (CSS) by TNF-alpha blockade. Immunobiology 2002; 206: 496–501
- Meller S, Gilliet M, Homey B. Chemokines in the pathogenesis of lichenoid tissue reactions. J Invest Dermatol 2009; 129: 315–19
- Taylor A, Pawaskar M, Taylor SL, Balkrishnan R, Feldman SR. Prevalence of pigmentary disorders and their impact on quality of life: a prospective cohort study. J Cosmet Dermatol 2008; 7: 164–8